Research Progress on the Role and Mechanism of IL-37 in Liver Diseases
暂无分享,去创建一个
Yanting Liu | Leyi Yao | Lingzhi Qi | Baojian Liao | Tieli Peng | Baoyi Jiang | Yulin Zhou | Siqi He | Yanting Liu
[1] C. Garlanda,et al. IL-1R8: A molecular brake of anti-tumor and anti-viral activity of NK cells and ILC. , 2023, Seminars in immunology.
[2] Qi Zhou,et al. Interleukin-37 suppresses the cytotoxicity of hepatitis B virus peptides-induced CD8+ T cells in patients with acute hepatitis B , 2022, Bosnian journal of basic medical sciences.
[3] G. López-Castejón,et al. NLRP3 inflammasome triggers interleukin‐37 release from human monocytes , 2022, European journal of immunology.
[4] Xiuhe Pan,et al. Protective Effects of Interleukin-37 Expression against Acetaminophen-Induced Hepatotoxicity in Mice , 2022, Evidence-based complementary and alternative medicine : eCAM.
[5] A. Sendelhofert,et al. Expression of IL-37 Correlates With Immune Cell Infiltrate and Fibrosis in Pediatric Autoimmune Liver Diseases , 2022, Journal of pediatric gastroenterology and nutrition.
[6] Jingchun Fan,et al. The Role of IL-37 and IL-38 in Colorectal Cancer , 2022, Frontiers in Medicine.
[7] X. Zhou,et al. Interleukin-37 promotes colitis-associated carcinogenesis via SIGIRR-mediated cytotoxic T cells dysfunction , 2022, Signal Transduction and Targeted Therapy.
[8] Mingyue Zhu,et al. IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma , 2021, Frontiers in Oncology.
[9] Yongyin Li,et al. Cytokines and Chemokines in HBV Infection , 2021, Frontiers in Molecular Biosciences.
[10] Shi‐Mei Zhuang,et al. Identification of a TGF-β/SMAD/lnc-UTGF positive feedback loop and its role in hepatoma metastasis , 2021, Signal Transduction and Targeted Therapy.
[11] A. Boonstra,et al. The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma , 2021, Cancers.
[12] H. Schiller,et al. IL‐37 regulates allergic inflammation by counterbalancing pro‐inflammatory IL‐1 and IL‐33 , 2021, Allergy.
[13] J. Birk,et al. A Review of Hepatitis B Virus and Hepatitis C Virus Immunopathogenesis , 2021, Journal of clinical and translational hepatology.
[14] L. Mishra,et al. TGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer , 2021, Gastroenterology.
[15] H. Tilg,et al. Modulation of Liver Inflammation and Fibrosis by Interleukin-37 , 2021, Frontiers in Immunology.
[16] Yulan Liu,et al. Neutrophil-Induced Liver Injury and Interactions Between Neutrophils and Liver Sinusoidal Endothelial Cells , 2021, Inflammation.
[17] Hao Wang,et al. IL-37 overexpression enhances therapeutic effect of endometrial regenerative cells in concanavalin A-induced hepatitis. , 2021, Cytotherapy.
[18] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[19] G. Szabo,et al. Immunopathobiology and therapeutic targets related to cytokines in liver diseases , 2020, Cellular & Molecular Immunology.
[20] F. Tacke,et al. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities , 2020, Cellular & molecular immunology.
[21] Tao Pan,et al. Shikonin blocks human lung adenocarcinoma cell migration and invasion in the inflammatory microenvironment via the IL-6/STAT3 signaling pathway , 2020, Oncology reports.
[22] A. El-Khoueiry,et al. Liver Cancer Immunity , 2020, Hepatology.
[23] G. Missale,et al. Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches , 2020, Frontiers in Immunology.
[24] A. Gehring,et al. Mechanisms of HBV immune evasion. , 2020, Antiviral research.
[25] P. He,et al. Interleukin-37 suppresses hepatocellular carcinoma growth through inhibiting M2 polarization of tumor-associated macrophages. , 2020, Molecular immunology.
[26] V. Angeli,et al. The indirect antiangiogenic effect of IL‐37 in the tumor microenvironment , 2020, Journal of leukocyte biology.
[27] Xianzhong Meng,et al. Interleukin 37 Suppresses M1 Macrophage Polarization Through Inhibition of the Notch1 and Nuclear Factor Kappa B Pathways , 2020, Frontiers in Cell and Developmental Biology.
[28] Kai Huang,et al. Decreased IL-37 expression in hepatocellular carcinoma tissues and liver cancer cell lines , 2020, Oncology letters.
[29] Yan Wang,et al. Low expression of IL-37 protein is correlated with high Oct4 protein expression in hepatocellular carcinoma. , 2020, Gene.
[30] M. L. de la Mata,et al. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma , 2020, International journal of molecular sciences.
[31] A. Satyanarayana,et al. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma , 2020, Cancers.
[32] S. Othman,et al. The potential role of interleukin-37 in infectious diseases , 2020, International reviews of immunology.
[33] Xiangxuan Zhao,et al. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer , 2019, Journal of Hematology & Oncology.
[34] Zujiang Yu,et al. Vaccinia virus expressing IL‐37 promotes antitumor immune responses in hepatocellular carcinoma , 2019, Cell biochemistry and function.
[35] Zhijun Luo,et al. Contextual Regulation of TGF-β Signaling in Liver Cancer , 2019, Cells.
[36] J. Gingold,et al. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma. , 2019, Trends in molecular medicine.
[37] J. Xia,et al. IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma , 2019, Cancer management and research.
[38] W. Ding,et al. The double-edged sword of MTOR in autophagy deficiency induced-liver injury and tumorigenesis , 2019, Autophagy.
[39] S. Kaneko,et al. Immune cell therapy for hepatocellular carcinoma , 2019, Journal of Hematology & Oncology.
[40] Xiaomo Wu,et al. Application of PD-1 Blockade in Cancer Immunotherapy , 2019, Computational and structural biotechnology journal.
[41] D. G. Osborne,et al. Interleukin‐37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome , 2019, Molecular carcinogenesis.
[42] P. Kubes,et al. The Neutrophil's Role During Health and Disease. , 2019, Physiological reviews.
[43] E. Seki,et al. Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets , 2019, Seminars in Liver Disease.
[44] G. Giannelli,et al. TGF-β as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives , 2018, Seminars in Liver Disease.
[45] Yigang Wang,et al. Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma , 2018, World journal of gastroenterology.
[46] C. Yun,et al. The Roles of Autophagy in Cancer , 2018, International journal of molecular sciences.
[47] A. Zlotnik,et al. Interleukin 30 to Interleukin 40. , 2018, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[48] I. Fabregat,et al. Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis , 2018, Front. Oncol..
[49] Jian-bo Zhang,et al. IL-37b suppresses epithelial mesenchymal transition in hepatocellular carcinoma by inhibiting IL-6/STAT3 signaling. , 2018, Hepatobiliary & pancreatic diseases international : HBPD INT.
[50] S. Ng,et al. The changing epidemiology of liver diseases in the Asia–Pacific region , 2018, Nature Reviews Gastroenterology & Hepatology.
[51] T. Liang,et al. Hepatitis B Virus Deregulates the Cell Cycle To Promote Viral Replication and a Premalignant Phenotype , 2018, Journal of Virology.
[52] H. Tilg,et al. Ethanol‐mediated suppression of IL‐37 licenses alcoholic liver disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[53] Bo Han,et al. Reviews of Interleukin-37: Functions, Receptors, and Roles in Diseases , 2018, BioMed research international.
[54] Ying Yang,et al. HBV Facilitated Hepatocellular Carcinoma Cells Proliferation by Up-Regulating Angiogenin Expression Through IL-6 , 2018, Cellular Physiology and Biochemistry.
[55] Jennifer R. Grandis,et al. Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.
[56] J. D. del Campo,et al. Role of inflammatory response in liver diseases: Therapeutic strategies , 2018, World journal of hepatology.
[57] Jiyoung Lee,et al. Autophagy and mitophagy in hepatocarcinogenesis , 2018, Molecular & cellular oncology.
[58] G. Cavalli,et al. Suppression of inflammation and acquired immunity by IL‐37 , 2018, Immunological reviews.
[59] S. Friedman,et al. Hepatic stellate cells as key target in liver fibrosis. , 2017, Advanced drug delivery reviews.
[60] R. Derynck,et al. Transforming Growth Factor-b Receptors and Smads : Regulatory Complexity and Functional Versatility , 2017 .
[61] S. Ikeda,et al. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies , 2017, Molecular Cancer.
[62] N. Sarvetnick,et al. Interleukin (IL)-18 Binding Protein Deficiency Disrupts Natural Killer Cell Maturation and Diminishes Circulating IL-18 , 2017, Front. Immunol..
[63] Zhongjun Wu,et al. IL‐37 induces autophagy in hepatocellular carcinoma cells by inhibiting the PI3K/AKT/mTOR pathway , 2017, Molecular immunology.
[64] D. Yoon,et al. Interleukin 32, inflammation and cancer , 2017, Pharmacology & therapeutics.
[65] Jason C Lao,et al. Monocytes and dendritic cells are the primary sources of interleukin 37 in human immune cells , 2017, Journal of leukocyte biology.
[66] Miaoyin Liang,et al. International incidence and mortality trends of liver cancer: a global profile , 2017, Scientific Reports.
[67] D. Sinnett,et al. A protective role of IL‐37 in cancer: a new hope for cancer patients , 2017, Journal of leukocyte biology.
[68] Ying Ju,et al. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients , 2017, Archives of Gynecology and Obstetrics.
[69] R. Liu,et al. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling , 2016, Oncotarget.
[70] Yujiang Fang,et al. The role of IL-37 in cancer , 2016, Medical Oncology.
[71] S. Dooley,et al. TGF‐β signalling and liver disease , 2016, The FEBS journal.
[72] Yi Lu,et al. Reciprocal activation between MMP-8 and TGF-β1 stimulates EMT and malignant progression of hepatocellular carcinoma. , 2016, Cancer letters.
[73] A. Hu,et al. Outcomes of Interferon/Ribavirin Therapy in Patients with HCV Defined by Expression of Plasma Soluble Human Leukocyte Antigen-G but Not IL-37 , 2016, Medical science monitor : international medical journal of experimental and clinical research.
[74] C. O’Farrelly,et al. Liver immunology and its role in inflammation and homeostasis , 2016, Cellular & Molecular Immunology.
[75] J. Schneider,et al. Autophagy and Metabolism , 2016 .
[76] L. Calvo,et al. Correction: IL6 Inhibits HBV Transcription by Targeting the Epigenetic Control of the Nuclear cccDNA Minichromosome , 2015, PloS one.
[77] B. Shen,et al. Long noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transition , 2015, Journal of Experimental & Clinical Cancer Research.
[78] S. Thorgeirsson,et al. Signal transducer and activator of transcription 3‐mediated CD133 up‐regulation contributes to promotion of hepatocellular carcinoma , 2015, Hepatology.
[79] J. Massagué,et al. Structural determinants of Smad function in TGF-β signaling. , 2015, Trends in biochemical sciences.
[80] R. Busuttil,et al. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. , 2015, World journal of hepatology.
[81] C. Feng,et al. IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study , 2015, BMC Gastroenterology.
[82] J. Whisstock,et al. IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction , 2015, Nature Immunology.
[83] H. Huber,et al. Axl activates autocrine transforming growth factor‐β signaling in hepatocellular carcinoma , 2015, Hepatology.
[84] H. Hsu,et al. The Effects of Cytokines on Spontaneous Hepatitis B Surface Antigen Seroconversion in Chronic Hepatitis B Virus Infection , 2015, The Journal of Immunology.
[85] T. Tung,et al. Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression , 2015, Clinical Cancer Research.
[86] M. Shirakawa,et al. The structural basis for receptor recognition of human interleukin-18 , 2014, Nature Communications.
[87] Zheng Zhang,et al. The global burden of liver disease: The major impact of China , 2014, Hepatology.
[88] Weiyu Chen,et al. MEF2 transcription factors promotes EMT and invasiveness of hepatocellular carcinoma through TGF-β1 autoregulation circuitry , 2014, Tumor Biology.
[89] M. Nicklin,et al. Long-range DNA interactions at the IL-1/IL-36/IL-37 gene cluster (2q13) are induced by activation of monocytes. , 2014, Cytokine.
[90] K. Pan,et al. Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells , 2014, Scientific Reports.
[91] D. Sahu,et al. TGF-β Mediated Crosstalk Between Malignant Hepatocyte and Tumor Microenvironment in Hepatocellular Carcinoma , 2014, Cancer growth and metastasis.
[92] Zhutian Zeng,et al. IL-12–Based Vaccination Therapy Reverses Liver-Induced Systemic Tolerance in a Mouse Model of Hepatitis B Virus Carrier , 2013, The Journal of Immunology.
[93] Yanfang Jiang,et al. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment. , 2013, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[94] K. Matsuzaki. Smad phospho-isoforms direct context-dependent TGF-β signaling. , 2013, Cytokine & growth factor reviews.
[95] D. Schuppan,et al. Evolving therapies for liver fibrosis. , 2013, The Journal of clinical investigation.
[96] Jing Zhao,et al. IL-17A but not IL-22 suppresses the replication of hepatitis B virus mediated by over-expression of MxA and OAS mRNA in the HepG2.2.15 cell line. , 2013, Antiviral research.
[97] R. Schuster,et al. Interleukin‐37 reduces liver inflammatory injury via effects on hepatocytes and non‐parenchymal cells , 2012, Journal of gastroenterology and hepatology.
[98] Limei Liu,et al. Combined Therapy with Cytokine-Induced Killer Cells and Oncolytic Adenovirus Expressing IL-12 Induce Enhanced Antitumor Activity in Liver Tumor Model , 2012, PloS one.
[99] K. Ryan,et al. Autophagy and cancer – issues we need to digest , 2012, Journal of Cell Science.
[100] A. Zychlinsky,et al. Neutrophil function: from mechanisms to disease. , 2012, Annual review of immunology.
[101] B. Gao,et al. Hepatoprotective and anti‐inflammatory cytokines in alcoholic liver disease , 2012, Journal of gastroenterology and hepatology.
[102] R. Kappler,et al. In Vivo Expression of Interleukin-37 Reduces Local and Systemic Inflammation in Concanavalin A-Induced Hepatitis , 2011, TheScientificWorldJournal.
[103] C. Dinarello,et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. , 2011, European cytokine network.
[104] S. Dooley,et al. TGF-β in progression of liver disease , 2011, Cell and Tissue Research.
[105] Li Yang,et al. Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment. , 2011, Gastroenterology.
[106] Yuquan Wei,et al. Proteomic analysis of the interleukin‐4 (IL‐4) response in hepatitis B virus‐positive human hepatocelluar carcinoma cell line HepG2.2.15 , 2011, Electrophoresis.
[107] S. Thorgeirsson,et al. Transforming growth factor‐β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer , 2008, Hepatology.
[108] S. Werner,et al. Active Caspase-1 Is a Regulator of Unconventional Protein Secretion , 2008, Cell.
[109] Katsunori Yoshida,et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocellular carcinoma , 2007, Hepatology.
[110] E. White,et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. , 2007, Genes & development.
[111] Xiang Gao,et al. IL-12 promotes HBV-specific central memory CD8+ T cell responses by PBMCs from chronic hepatitis B virus carriers. , 2007, International immunopharmacology.
[112] X. Wang,et al. The role of cytokines in hepatocellular carcinoma , 2006, Journal of leukocyte biology.
[113] Ivan Rusyn,et al. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[114] C. Dinarello,et al. Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. , 2004, The Biochemical journal.
[115] Govind Bhagat,et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. , 2003, The Journal of clinical investigation.
[116] Sue-Jane Lin,et al. IL-4 Suppresses the Expression and the Replication of Hepatitis B Virus in the Hepatocellular Carcinoma Cell Line Hep3B 1 , 2003, The Journal of Immunology.
[117] C. Dinarello,et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[118] John C. Lee,et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. , 2002, Cytokine.
[119] G. McCaughan,et al. Cytokines and chemokines in the immune response to hepatitis C infection , 2001, Current opinion in infectious diseases.
[120] M. Doyle,et al. Identification and Initial Characterization of Four Novel Members of the Interleukin-1 Family* , 2000, The Journal of Biological Chemistry.
[121] P. Marcellin,et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. , 2000, Journal of hepatology.
[122] Y. Chawla,et al. Immunology of hepatocellular carcinoma. , 1991, The Italian journal of gastroenterology.
[123] Guohong Deng,et al. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. , 2019, Journal of hepatology.
[124] Raja Mazumder,et al. Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-β Pathway. , 2018, Gastroenterology.
[125] R. Brůha,et al. Alcoholic liver disease. , 2012, World journal of hepatology.
[126] R. Schwabe,et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. , 2010, Gastroenterology.
[127] R. Ortíz-López,et al. Oncolytic virotherapy. , 2008, Annals of hepatology.
[128] Katsunori Yoshida,et al. Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. , 2005, The American journal of pathology.
[129] M. Pinzani. Liver fibrosis , 2004, Springer Seminars in Immunopathology.
[130] B. Stefanovic,et al. Fibrogenesis. III. Posttranscriptional regulation of type I collagen. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[131] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.